Overview

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
Phase:
Phase 2
Details
Lead Sponsor:
Rabin Medical Center
Treatments:
Pembrolizumab